Shinjiro Sakamoto

Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer

Yu Nakanishi, Takeshi Masuda, Kakuhiro Yamaguchi et al. · Respiratory Investigation · 2019 · 119 citations

Medicine, Immunology, Oncology +16

<scp>PD</scp>‐1 expression on peripheral blood T‐cell subsets correlates with prognosis in non‐small cell lung cancer

Kayoko Waki, Teppei Yamada, Koichi Yoshiyama et al. · Cancer Science · 2014 · 93 citations · Full text

Medicine, Immunology, Oncology +16

Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor–Induced Interstitial Lung Disease Among Patients With Nonlung Cancers

Kiyofumi Shimoji, Takeshi Masuda, Kakuhiro Yamaguchi et al. · JAMA Network Open · 2020 · 68 citations · Full text

Medicine, Immunology, Oncology +15

Preserved ratio impaired spirometry with or without restrictive spirometric abnormality

Shin‐ichiro Miura, Hiroshi Iwamoto, Keitaro Omori et al. · Scientific Reports · 2023 · 58 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +13

Inhibition of PAI‐1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer‐associated fibroblasts

Takeshi Masuda, Taku Nakashima, Masashi Namba et al. · Journal of Cellular and Molecular Medicine · 2019 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17